Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Infectious & Toxicology
Filter     Order     Display # 
Date Item Title Hits
15 Mar 2010 Vacc-C5 to be prepared for phase I/II clinical trial 5
15 Mar 2010 Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 3
15 Mar 2010 MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I 3
12 Mar 2010 TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints 7
11 Mar 2010 Pharmaxis completes phase II clinical study with ASM8 in asthma patients 7
11 Mar 2010 Request for re-examination of ceftobiprole submitted to CHMP 6
11 Mar 2010 Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development 4
11 Mar 2010 PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010 5
11 Mar 2010 Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 5
11 Mar 2010 Baxter Presents Clinical Efficacy Results from Phase III Study of Seasonal Flu Vaccine 5
10 Mar 2010 Cempra Announces the Completion of Phase 1 Studies for CEM-101, a Next-Generation Macrolide 8
09 Mar 2010 Successful Development of Broad Spectrum Human Monoclonal Antibodies Against Major Influenza Viruses (H1N1 and H5N1) 8
09 Mar 2010 Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 4
04 Mar 2010 Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis HIV Program in Clinical Immunology 9
04 Mar 2010 BioVex Initiates Phase 1 Clinical Trial with Its Genital Herpes Vaccine, ImmunoVEXHSV2 29
02 Mar 2010 Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program 7
02 Mar 2010 Abbott and Enanta Announce Advancement of Hepatitis C Collaboration 24
01 Mar 2010 Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies 6
25 Feb 2010 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 81
24 Feb 2010 Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 11
24 Feb 2010 Pfizer Receives FDA Approval for Prevnar 13 for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children 12
24 Feb 2010 Publication of Vical's H5N1 Results Paves the Way for H1N1 Clinical Trial 14
24 Feb 2010 Entered into Global Partnership with Basilea for an Azole Antifungual Agent Isavuconazole 11
24 Feb 2010 ANA598 Demonstrates 73% cEVR in Combination With Interferon and Ribavirin 13
23 Feb 2010 GlycoVaxyn's First Clinical Study with Bioconjugate Vaccine Initiated 16
22 Feb 2010 Cyto Pulse, the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers 13
22 Feb 2010 Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection 12
22 Feb 2010 Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease 12
22 Feb 2010 U.S. Food and Drug Administration Approves Cayston® (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa 10
19 Feb 2010 Sanofi Pasteur’s A(H1N1) Vaccine Humenza Recommended by European Medicines Agency 21
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1868

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics